Carboplatin plus vinorelbine, a new well-tolerated and active regimen for the treatment of extensive-stage small-cell lung cancer: A phase II study

Journal of Clinical Oncology

Volumn 16, Issue 4, 1998, Pages 1414-1419

  Gridelli, Cesare ^a   Perrone, Francesco ^a   Ianniello, Giovanni P ^a   Brancaccio, Luigi ^a   laffaioli, Rosario Vincenzo ^a   Curcio, Carlo ^a   D'Aprile, Modesto ^a   Cioffi, Riccardo ^a   Cigolari, Silvio ^a   Rossi, Antonio ^a   Palazzolo, Giovanni ^a   Veltri, Enzo ^a   Pergola, Mario ^a   De Placido, Sabino ^a   Gallo, Ciro ^a   Monfardini, Silvio ^a   Bianco, Angelo Raffaele ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CISPLATIN; NAVELBINE;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANEMIA; ARTICLE; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; DOSE RESPONSE; DRUG TOLERABILITY; EXTRAVASATION; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LEUKOPENIA; LUNG SMALL CELL CANCER; MALE; MULTICENTER STUDY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; THROMBOCYTOPENIA; VOMITING;

EID: 0031923345     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1998.16.4.1414     Document Type: Article

References (38)

1. Ihde DC: Current status of therapy for small-cell lung carcinoma of the lung. Cancer 2:2722-2728, 1984
2. Feld R, Evans WK, De Boer G, et al: Combined modality induction therapy without maintenance chemotherapy for small-cell carcinoma of the lung. J Clin Oncol 2:294-304, 1984
3. Aisner J, Whitacre M, Abrams J, et al: Doxorubicin, cyclophosphamide, etoposide and platinum, doxorubicin, cyclophosphamide and etoposide for small-cell lung carcinoma of the lung. J Clin Oncol 3:54-62, 1986 (suppl 3)
4. Einhorn LH: Initial therapy with cisplatin plus VP-16 in small-cell lung cancer. Semin Oncol 13:5-9, 1986 (suppl)
5. Miles DW, Fogarty O, Asch CM, et al: Received dose-intensity: A randomized trial of weekly chemotherapy with and without granulocyte colony-stimulating factor in small-cell lung cancer. J Clin Oncol 12:77-82, 1994
6. Pujol JL, Donvillard JY, Riviere A, et al: Dose-intensity of a four-drug chemotherapy regimen with or without recombinant human granulocyte-macrophage colony-stimulating factor in extensive stage small-cell lung cancer: A multicenter randomized phase III study. J Clin Oncol 15:2082-2089, 1997
7. Smith IE, Evans BD: Carboplatin (JM8) as a single agent and in combination in the treatment of small-cell lung cancer. Cancer Treat Rev 12:73-75, 1985
8. Jacobs RH, Bitran J, Deutsch M, et al: Phase II study of carboplatin in previously untreated patients with metastatic small-cell lung carcinoma. Cancer Treat Rep 71:311-312, 1987
9. Kosmidis PA, Samantas E, Fountzilas G, et al: Cisplatin/etoposide versus carboplatin/etoposide chemotherapy and irradiation in small-cell lung cancer: A randomized phase III study. Semin Oncol 21:23-30, 1994 (suppl 3)
10. Lassen U, Kristjansen PEG, Osterlind K, et al: Superiority of cisplatin or carboplatin in combination with teniposide and vincristine in the induction chemotherapy of small-cell lung cancer. Ann Oncol 7:365-371, 1996
11. Jassem J, Karniche-Mlodkowoka H, van Pottelsberghe C, et al: Phase II study of vinorelbine (navelbine) in previously treated small-cell lung cancer patients. Eur J Cancer 29A: 1720-1722, 1993
12. Furuse K, Kubota K, Kawahara M, et al: Phase II study of vinorelbine in heavily previously treated small-cell lung cancer. Oncology 53:169-172, 1996
13. Lake D, Johnson E, Herndon J, et al: Phase II trial of navelbine (NVB) in relapsed small-cell lung cancer (SCLC). Proc Am Soc Clin Oncol 16:473A, 1997 (abstr)
14. Depierre A, Le Chevalier T, Quoix E, et al: Phase II study of navelbine (NVB) in small-cell lung cancer (SCLC). Proc Am Soc Clin Oncol 14:348, 1995 (abstr)
15. Simon R: Optimal two-stage designs for phase II clinical trials. Controlled Clin Trials 10:1-10, 1989
16. Jelliffe RW: Creatinine clearance: Bedside estimate. Ann Intern Med 79:604-605, 1973
17. Calvert AH, Newell DR, Gumbrell LA, et al: Carboplatin dosage: Prospective evaluation of a simple formula based on renal function. J Clin Oncol 7:1748-1756, 1989
18. Miller AB, Hoogstraten B, Staquet M, et al: Reporting results of cancer treatment. Cancer 47:207-214, 1981
19. Lentner C (ed): Geigy Scientific Tables. Boyle, Switzerland, Ciba-Geigy, Ltd, 1982
20. Kaplan EL, Meier P: Nonparametric estimation from incomplete observation. J Am Stat Assoc 53:457-481, 1958
21. Dixon WJ: BMDP Statistical Software. Los Angeles, CA, University of California Press, 1992
22. Brookmeyer R, Crowley G: A confidence interval for the median survival time. Biometrics 38:29-41, 1982
23. Bishop JF, Raghavan D, Stuart-Harris R, et al: Carboplatin (CBDCA, JM8) and VP-16-213 in previously untreated patients with small-cell lung cancer. J Clin Oncol 5:1574-1578, 1987
24. Smith IE, Evans BD, Gore ME, et al: Carboplatin (Paraplatin, JM8) and etoposide (VP-16) as first-line combination therapy for small-cell lung cancer. J Clin Oncol 5:185-189, 1987
25. Evans WK, Eisenhauer E, Hughes P, et al: VP-16 and carboplatin in previously untreated patients with extensive small-cell lung cancer: A study of National Cancer Institute of Canada Clinical Trial Group. Br J Cancer 58:464-468, 1988
26. Evans WK, Sheperd FA, Feld R, et al: First line therapy with VP-16 and cisplatin for small cell lung cancer. Semin Oncol 13:17-23, 1986 (suppl 3)
27. Miyamoto H, Nakabayashi T, Isobe H, et al: A phase III comparison of etoposide/cisplatin with or without added ifosfamide in small-cell lung cancer. Oncology 49:431-435, 1992
28. Loehrer PJ, Ansari R, Gonin R, et al: Cisplatin plus etoposide with and without ifosfamide in extensive small-cell lung cancer: A Hoosier Oncology Group Study. J Clin Oncol 13:2594-2599, 1995
29. Ihde D, Mulshine JL, Kramer BS, et al: Prospective randomized comparison of high-dose and standard-dose etoposide and cisplatin chemotherapy in patients with extensive-stage small-cell lung cancer. J Clin Oncol 12:2022-2034, 1994
30. Souhami RL, Rudd R, Ruiz de Elvira MC, et al: Randomized trial comparing weekly versus 3-week chemotherapy in small-cell lung cancer: A Cancer Research Campaign Trial. J Clin Oncol 12:1806-1813, 1994
31. Gridelli C, Ianniello GP, Maiorino A, et al: Carboplatin, epirubicin, and VP-16 chemotherapy in the treatment of small-cell lung cancer. Am J Clin Oncol 17:160-162, 1994
32. Gatzmeier U, Pawel JV, Lannen R, et al: Etoposide/vincristine-based chemotherapy with or without carboplatin in extensive-stage small-cell lung cancer: A prospective randomized phase III trial. Semin Oncol 21:31-35, 1994 (suppl 6)
33. Wolff AC, Ettinger DS, Nenberg D, et al: Phase II study of ifosfamide, carboplatin, and oral etoposide chemotherapy for extensive-disease small-cell lung cancer: An Eastern Cooperative Oncology Group pilot study. J Clin Oncol 13:1615-1622, 1995
34. Gridelli C, D'Aprile M, Palmen S, et al: Phase I study of chemotherapy with carboplatin, epirubicin, and escalating dose of VP-16 with G-CSF support in extensive small-cell lung cancer. Am J Clin Oncol 19:589-591, 1996
35. Gridelli C, Perrone F, D'Aprile M, et al: Phase II study of intensive CEV (carboplatin, epirubicin and VP-16) plus G-CSF (granulocyte-colony stimulating factor) in extensive small cell lung cancer. Eur J Cancer 31A:2424-2426, 1995
36. Schiller J, Kim K, Hutson P, et al: Phase II study of topotecan in patients with extensive-stage small-cell carcinoma of the lung: An Eastern Cooperative Oncology Group Trial. J Clin Oncol 14:2345-2352, 1996
37. Cormier Y, Eisenhauer E, Muldal A, et al: Gemcitabine is an active new agent in previously untreated extensive small-cell lung cancer (SCLC). Ann Oncol 5:283-285, 1994
38. Ettinger DS, Finkelstein DM, Sarma P, et al: Phase II study of paclitaxel in patients with extensive-disease small-cell lung cancer: An Eastern Cooperative Oncology Group Study. J Clin Oncol 13:1430-1435, 1995